Ramsey Imogen, Kennedy Kate, Sharplin Greg, Eckert Marion, Peters Micah D J
Rosemary Bryant AO Research Centre, Clinical & Health Sciences, University of South Australia, Adelaide, Australia.
Faculty of Health and Medical Sciences, Adelaide Nursing School, The University of Adelaide, Adelaide, Australia.
Int J Transgend Health. 2023 Jan 13;24(2):174-194. doi: 10.1080/26895269.2022.2155289. eCollection 2023.
There is a recognized need for evidence to inform breast cancer screening guidelines and services for transgender people, who face barriers to accessing appropriate and inclusive health care.
This review summarized evidence for breast cancer risk and screening guidelines in transgender individuals, including the potential impact of gender-affirming hormone therapy (GAHT); factors that may influence screening decision-making and behaviors; and considerations for providing culturally safe, high-quality screening services.
A protocol was developed based on the Joanna Briggs Institute scoping review methodology. Searches were performed in Medline, Emcare, Embase, Scopus, and the Cochrane Library for articles reporting information on the provision of culturally safe, high-quality breast cancer screening services for transgender people.
We identified 57 sources for inclusion: 13 cross-sectional studies, 6 case reports, 2 case series, 28 review or opinion articles, 6 systematic reviews, 1 qualitative study, and 1 book chapter. Evidence on rates of breast cancer screening among transgender people and the association between GAHT and breast cancer risk was inconclusive. Factors negatively associated with cancer screening behaviors included socioeconomic barriers, stigma, and lack of health provider awareness of transgender health issues. Breast cancer screening recommendations varied and were generally based on expert opinion due to the lack of clear evidence. Considerations for providing culturally safe care to transgender people were identified and mapped to the areas of workplace policies and procedures, patient information, clinic environment, professional conduct, communication, and knowledge and competency.
Screening recommendations for transgender individuals are complicated by the lack of robust epidemiological data and clear understanding of the role GAHT may play in breast cancer pathogenesis. Guidelines have been developed based on expert opinion and are subsequently not uniform or evidence based. Further work is required to clarify and consolidate recommendations.
人们认识到需要有证据来为跨性别者的乳腺癌筛查指南和服务提供信息,因为他们在获得适当和包容的医疗保健方面面临障碍。
本综述总结了跨性别者乳腺癌风险和筛查指南的证据,包括性别确认激素疗法(GAHT)的潜在影响;可能影响筛查决策和行为的因素;以及提供具有文化安全性、高质量筛查服务的注意事项。
根据乔安娜·布里格斯研究所的范围综述方法制定了一项方案。在Medline、Emcare、Embase、Scopus和Cochrane图书馆中进行检索,以查找报告为跨性别者提供具有文化安全性、高质量乳腺癌筛查服务信息的文章。
我们确定了57篇纳入文献:13项横断面研究、6篇病例报告、2个病例系列、28篇综述或观点文章、6项系统评价、1项定性研究和1章书籍内容。关于跨性别者乳腺癌筛查率以及GAHT与乳腺癌风险之间关联的证据尚无定论。与癌症筛查行为呈负相关的因素包括社会经济障碍、耻辱感以及医疗服务提供者对跨性别者健康问题缺乏认识。由于缺乏明确证据,乳腺癌筛查建议各不相同,且通常基于专家意见。确定了为跨性别者提供具有文化安全性护理的注意事项,并将其映射到工作场所政策和程序、患者信息、诊所环境、专业行为、沟通以及知识和能力等领域。
由于缺乏有力的流行病学数据以及对GAHT在乳腺癌发病机制中可能发挥的作用缺乏清晰认识,跨性别者的筛查建议变得复杂。指南是基于专家意见制定的,因此并不统一或缺乏循证基础。需要进一步开展工作以澄清和巩固建议。